Literature DB >> 19839427

Radical prostatectomy reigns supreme.

Heidi J Rayala1, Jerome P Richie.   

Abstract

The clinical incidence of prostate cancer continues to increase in the patient population, while the actual mortality has remained relatively low. As clinicians, we struggle to identify those patients who require intervention for their disease and to determine which treatment modality is best. Active surveillance, brachytherapy, external-beam radiation therapy, and surgical radical prostatectomy (RP) are the current options for prostate cancer treatment, each with a distinct impact on a patient's health-related quality of life. We believe that for the majority of patients with organ-confined prostate cancer, RP remains the gold standard with respect to both oncologic success and maximization of quality of life. Herein we discuss the advantages of RP.

Entities:  

Mesh:

Year:  2009        PMID: 19839427

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

1.  The association between tumour density and prostate cancer recurrence following radical prostatectomy.

Authors:  Luke T Lavallée; Rodney H Breau; Mark A Preston; Gayanna Raju; Christopher Morash; Steve Doucette; Ronald G Gerridzen; James Eastham; Ilias Cagiannos
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

2.  Contemporary radical prostatectomy.

Authors:  Qiang Fu; Judd W Moul; Leon Sun
Journal:  Prostate Cancer       Date:  2011-04-14

3.  Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer.

Authors:  David Schreiber; Justin Rineer; Jeffrey P Weiss; Joseph Safdieh; Joseph Weiner; Marvin Rotman; David Schwartz
Journal:  Radiat Oncol J       Date:  2015-03-31

4.  VaccImm: simulating peptide vaccination in cancer therapy.

Authors:  Joachim von Eichborn; Anna Lena Woelke; Filippo Castiglione; Robert Preissner
Journal:  BMC Bioinformatics       Date:  2013-04-15       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.